-
LINEPHARMA submits abortion drug license application in Japan
Time of Update: 2022-03-10
This drug is considered the international gold standard for medical abortion in early pregnancyi and is included in the World Health Organization (WHO) List of Essential Medicines for Abortion .
-
Tianyu Pharmaceutical's rivaroxaban API obtained CEP certificate
Time of Update: 2022-03-09
On January 27, Tianyu Pharmaceutical announced that the company received the CEP certificate for rivaroxaban API issued by the European Agency for the Quality of Medicines .
In October 2020, the company submitted a drug registration application for rivaroxaban API to EDQM and obtained a CEP certificate .
-
Omicron's new vaccine!
Time of Update: 2022-03-09
On January 25, Pfizer and BioNTech jointly announced the initiation of a clinical trial to evaluate the protective efficacy of Omicron's proprietary vaccine in healthy adults aged 18-55 .
com/Investors/News/news-details/2022/Pfizer-and-BioNTech-Initiate-Study-to-Evaluate-Omicron-Based-COVID-19-Vaccine-in-Adults- 18-to-55-Years-of-Age/default.
-
Copy PD-1?
Time of Update: 2022-03-09
If we go back, as early as when Innovent and Eli Lilly expanded their strategic cooperation, the PD-1/TIGIT double antibody jointly developed by them is another sense of "going overseas" .
-
The 2nd China-made Wanbang Pharmaceutical "Insulin Lispro" was approved for listing
Time of Update: 2022-03-09
On January 26, NMPA issued an approval document showing that Wanbang Pharmaceutical's insulin lispro injection was approved for marketing, becoming the second domestic company .
Previously, only Lilly and Gan & Lee's insulin lispro were approved for marketing in China .
-
HER2-ADC drugs enter the intensive harvest period, can ARX788 support the transformation of Zhejiang medicine?
Time of Update: 2022-03-09
TextXu Libo, AmphetamineThe clinical application of the recombinant humanized anti-HER2 monoclonal antibody-AS269 conjugate (ARX788) for injection, which is used for the treatment of HER2-positive advanced breast cancer and gastric cancer, has been accepted by Xinma Bio, a subsidiary of Zhejiang Medicine .
-
Kexing's 770 million foray into real estate Pien Tze Huang's repeated defeats and repeated battles in the pharmaceutical industry's infrastructure business, how is it?
Time of Update: 2022-03-09
8 billion yuan, and the engineering construction investment of the Pien Tze Huang Health and Beauty Park project is about 1.
-
As a drugmaker, don't "call back" when the FDA answers questions
Time of Update: 2022-03-09
"Source: Anhui Provincial Drug AdministrationNetizens ask whether they are eligible to register for the examination of the drug administration system, and reply "I have replied to your inquiry by phone .
-
Another city!
Time of Update: 2022-03-09
Recently, Hengrui Medicine's Class 1 new drug Proline Henggliflozin Tablets (trade name: Ruiqin) was officially approved for marketing, which is also the first domestically-made innovative SGLT2 inhibitor approved so far .
-
Children's drug market, there is still a lot of space to be tapped
Time of Update: 2022-03-09
At present, the size of China's children's drug market accounts for about 5% of the entire pharmaceutical industry.
In order to solve the problem of expensive treatment of children's medicines, especially children's rare disease medicines, relevant departments such as the National Medical Insurance Administration are also constantly trying to find ways .
-
Hongri Pharmaceutical's Enoxaparin Sodium Injection Approved for Marketing in the Prevention and Treatment of Thrombotic or Embolic Diseases
Time of Update: 2022-03-09
As the first heparin drug that has been reviewed by three companies, the domestic market of enoxaparin sodium injection has continued to expand in recent years, with terminal sales of more than 2.
-
Pfizer names 6 general managers for new business units
Time of Update: 2022-03-09
He has over 20 years of experience in the Chinese pharmaceutical industry and has held a range of positions including National Sales Director, Marketing Director and Marketing Manager .
She joined Pfizer in 2020 with over 20 years of experience in market access and public affairs in the pharmaceutical industry .
-
Two new class 1 drugs of Haisco have entered the new field and new indications of innovative drugs in anesthesia are here
Time of Update: 2022-03-09
On February 8th, the good news of Hisco's innovative drugs continued: Class 1 new drugs HSK31858 tablets and HSK31679 tablets were approved for clinical use, and the new drug clinical application for HSK36212 capsules was also undertaken by CDE; in addition, the company's cyclopofol injection, which was approved for marketing in 2020 The listing application for the sixth indication of the liquid has also been accepted.
-
China Securities Regulatory Commission terminates the issuance and registration of Bite Pharmaceuticals on the Growth Enterprise Market
Time of Update: 2022-03-09
on the withdrawal of the initial public offering and the Application for Listing Application Documents on the Growth Enterprise Market” (Xingbei Yaozi [2021] No.
475) and “Application for Withdrawing the Application Documents for the Initial Public Offering of Shares by Chengdu Better Pharmaceutical Co.
-
Junjing Bio's Aurora A Inhibitor Approved for Clinical Treatment of Advanced Cancer in China
Time of Update: 2022-03-09
TextPharmaceutical GuanlanThe official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China recently announced that the Class 1 new drug WJ05129 tablets declared by Junjing Bio has obtained the implied license for clinical trials and is intended to be used for advanced cancers for which there is currently no effective treatment .
-
Changes to drug prices after DRG implementation
Time of Update: 2022-03-09
Chart: Generic Drug Substitution Ratio of Various Types of Institutions in Japan in 2020Data source: Japanese Ministry of Health, Labour and Welfare, Latitude Health analysisIf we look at various regions, the regions with a high substitution rate of DPC inpatient generic drugs have a correspondingly higher substitution rate of outpatient and prescription retail, which means that the medication habits of the entire region have changed significantly at the same time .
-
The reform of centralized procurement is imperative for the centralized procurement of proprietary Chinese medicines without restricted areas
Time of Update: 2022-03-09
According to a report by China Medical Insurance, 182 products from 157 companies participated in the bidding for this round of centralized procurement of proprietary Chinese medicines in 19 provinces, with a procurement scale of nearly 10 billion yuan; the final 97 Companies and 111 products were selected, with a selection rate of 62%.
-
Simcere Pharma Appoints Zhou Gaobo as Chief Investment Officer
Time of Update: 2022-03-09
On January 17, Simcere announced the appointment of Zhou Gaobo as chief investment officer, responsible for the company's innovative drug investment and business expansion, new investment platform construction, and strategic planning and practice.
Before joining Simcere, Mr.
-
Is the future of Chinese medicine really beautiful?
Time of Update: 2022-03-09
Core content of the "Guiding Opinions on Medical Insurance Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine"Source: State Administration of Traditional Chinese Medicine website, Zhongkang Industrial Capital Research CenterFrom the core content of the "Guiding Opinions", it can be seen that traditional Chinese medicine medical services benefit the most from it.
-
This week, 11 new class 1 drugs were approved for clinical use!
Time of Update: 2022-03-09
According to an earlier press release from Bangshun Pharmaceuticals, OB756 is an oral selective JAK2 inhibitor independently developed by the company, which can exert therapeutic effects by targeting the kinase activity of JAK2 V617F and blocking the JAK/STAT signaling pathway .
